GILD · 10-Q · 2026Q3 · Full report

Veklury Sales Decline

GILEAD SCIENCES, INC. · 2026-10-30 · Importance 10 · Surprise 64

Veklury product sales fell 69% to $86 million in the third quarter of 2026 and 64% to $253 million for the first nine months. The filing attributes the declines to lower rates of COVID-19-related hospitalizations. The reported contraction was substantial year over year in both periods.

Key facts

• Gilead’s Veklury sales decreased 69% to $86 million in Q3 2026 and 64% to $253 million for the first nine months of 2026, primarily due to lower COVID-19-related hospitalizations. source